BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 29112956)

  • 1. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
    Henrich TJ; Hatano H; Bacon O; Hogan LE; Rutishauser R; Hill A; Kearney MF; Anderson EM; Buchbinder SP; Cohen SE; Abdel-Mohsen M; Pohlmeyer CW; Fromentin R; Hoh R; Liu AY; McCune JM; Spindler J; Metcalf-Pate K; Hobbs KS; Thanh C; Gibson EA; Kuritzkes DR; Siliciano RF; Price RW; Richman DD; Chomont N; Siliciano JD; Mellors JW; Yukl SA; Blankson JN; Liegler T; Deeks SG
    PLoS Med; 2017 Nov; 14(11):e1002417. PubMed ID: 29112956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
    Aamer HA; McClure J; Ko D; Maenza J; Collier AC; Coombs RW; Mullins JI; Frenkel LM
    PLoS Pathog; 2020 Aug; 16(8):e1008791. PubMed ID: 32841299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.
    Kearney MF; Wiegand A; Shao W; Coffin JM; Mellors JW; Lederman M; Gandhi RT; Keele BF; Li JZ
    J Virol; 2016 Feb; 90(3):1369-76. PubMed ID: 26581989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption.
    Prator CA; Thanh C; Kumar S; Pan T; Peluso MJ; Bosch R; Jones N; Milush JM; Bakkour S; Stone M; Busch MP; Deeks SG; Hunt PW; Henrich TJ
    J Infect Dis; 2020 Mar; 221(7):1146-1155. PubMed ID: 31677350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites.
    Lee E; von Stockenstrom S; Morcilla V; Odevall L; Hiener B; Shao W; Hartogensis W; Bacchetti P; Milush J; Liegler T; Sinclair E; Hatano H; Hoh R; Somsouk M; Hunt P; Boritz E; Douek D; Fromentin R; Chomont N; Deeks SG; Hecht FM; Palmer S
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31723024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance between HIV-1 Population in Plasma at Rebound after Structured Treatment Interruption and Archived Provirus Population in Peripheral Blood Mononuclear Cells.
    Hendricks CM; Cash MN; Tagliamonte MS; Riva A; Brander C; Llano A; Salemi M; Stevenson M; Mavian C
    Microbiol Spectr; 2022 Aug; 10(4):e0135322. PubMed ID: 35699458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.
    Crowell TA; Colby DJ; Pinyakorn S; Sacdalan C; Pagliuzza A; Intasan J; Benjapornpong K; Tangnaree K; Chomchey N; Kroon E; de Souza MS; Tovanabutra S; Rolland M; Eller MA; Paquin-Proulx D; Bolton DL; Tokarev A; Thomas R; Takata H; Trautmann L; Krebs SJ; Modjarrad K; McDermott AB; Bailer RT; Doria-Rose N; Patel B; Gorelick RJ; Fullmer BA; Schuetz A; Grandin PV; O'Connell RJ; Ledgerwood JE; Graham BS; Tressler R; Mascola JR; Chomont N; Michael NL; Robb ML; Phanuphak N; Ananworanich J;
    Lancet HIV; 2019 May; 6(5):e297-e306. PubMed ID: 31000477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a Novel Humanized Mouse Model To Investigate
    Flerin NC; Bardhi A; Zheng JH; Korom M; Folkvord J; Kovacs C; Benko E; Truong R; Mota T; Connick E; Jones RB; Lynch RM; Goldstein H
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30626677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen Presenting Cells Contribute to Persistent Immune Activation Despite Antiretroviral Therapy Initiation During Hyperacute HIV-1 Infection.
    Naidoo KK; Ndumnego OC; Ismail N; Dong KL; Ndung'u T
    Front Immunol; 2021; 12():738743. PubMed ID: 34630420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption.
    Vibholm LK; Lorenzi JCC; Pai JA; Cohen YZ; Oliveira TY; Barton JP; Garcia Noceda M; Lu CL; Ablanedo-Terrazas Y; Del Rio Estrada PM; Reyes-Teran G; Tolstrup M; Denton PW; Damsgaard T; Søgaard OS; Nussenzweig MC
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30700598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells.
    Buzon MJ; Martin-Gayo E; Pereyra F; Ouyang Z; Sun H; Li JZ; Piovoso M; Shaw A; Dalmau J; Zangger N; Martinez-Picado J; Zurakowski R; Yu XG; Telenti A; Walker BD; Rosenberg ES; Lichterfeld M
    J Virol; 2014 Sep; 88(17):10056-65. PubMed ID: 24965451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virologic and Immunologic Features of Simian Immunodeficiency Virus Control Post-ART Interruption in Rhesus Macaques.
    Strongin Z; Micci L; Fromentin R; Harper J; McBrien J; Ryan E; Shenvi N; Easley K; Chomont N; Silvestri G; Paiardini M
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32350073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption.
    Li JZ; Etemad B; Ahmed H; Aga E; Bosch RJ; Mellors JW; Kuritzkes DR; Lederman MM; Para M; Gandhi RT
    AIDS; 2016 Jan; 30(3):343-53. PubMed ID: 26588174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.
    Cummins NW; Rizza S; Litzow MR; Hua S; Lee GQ; Einkauf K; Chun TW; Rhame F; Baker JV; Busch MP; Chomont N; Dean PG; Fromentin R; Haase AT; Hampton D; Keating SM; Lada SM; Lee TH; Natesampillai S; Richman DD; Schacker TW; Wietgrefe S; Yu XG; Yao JD; Zeuli J; Lichterfeld M; Badley AD
    PLoS Med; 2017 Nov; 14(11):e1002461. PubMed ID: 29182633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
    Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals.
    Clarridge KE; Blazkova J; Einkauf K; Petrone M; Refsland EW; Justement JS; Shi V; Huiting ED; Seamon CA; Lee GQ; Yu XG; Moir S; Sneller MC; Lichterfeld M; Chun TW
    PLoS Pathog; 2018 Jan; 14(1):e1006792. PubMed ID: 29324842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.
    Frange P; Faye A; Avettand-Fenoël V; Bellaton E; Descamps D; Angin M; David A; Caillat-Zucman S; Peytavin G; Dollfus C; Le Chenadec J; Warszawski J; Rouzioux C; Sáez-Cirión A;
    Lancet HIV; 2016 Jan; 3(1):e49-54. PubMed ID: 26762993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test.
    Jagodzinski LL; Manak MM; Hack HR; Liu Y; Malia JA; Freeman J; Phanuphak N; de Souza M; Kroon ED; Colby DJ; Chomchey N; Lally MA; Michael NL; Ananworanich J; Peel SA;
    J Clin Microbiol; 2019 May; 57(5):. PubMed ID: 30842229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid development of HIV elite control in a patient with acute infection.
    Morley D; Lambert JS; Hogan LE; De Gascun C; Redmond N; Rutishauser RL; Thanh C; Gibson EA; Hobbs K; Bakkour S; Busch MP; Farrell J; McGetrick P; Henrich TJ
    BMC Infect Dis; 2019 Sep; 19(1):815. PubMed ID: 31533639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription.
    Pannus P; Rutsaert S; De Wit S; Allard SD; Vanham G; Cole B; Nescoi C; Aerts J; De Spiegelaere W; Tsoumanis A; Couttenye MM; Herssens N; De Scheerder MA; Vandekerckhove L; Florence E
    J Int AIDS Soc; 2020 Feb; 23(2):e25453. PubMed ID: 32107887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.